Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The hypotheses under test are that subjects with alcohol use disorder (AUD) of moderate or
greater severity treated with CORT118335 will report decreased craving for alcohol following
alcohol exposure in the laboratory and report significantly less drinking under naturalistic
conditions, than those treated with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
The Scripps Research Institute
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)